Moderna Shares Surge 150% on Positive mRNA Cancer Vaccine Results

Moderna's stock experienced a significant surge of approximately 150% on August 19 following the announcement of positive Phase 3 results for a personalized mRNA treatment aimed at combating melanoma. The companies, Moderna and Merck, collaborated in a clinical trial involving 1,137 patients who had undergone surgical removal of high-risk melanoma.

The treatment, known as intismeran autogene or V940/mRNA-4157, combined with Merck’s Keytruda, demonstrated success in delaying cancer recurrence and reducing the risk of distant metastasis as per the trial's main objective. This marks the first successful Phase 3 outcome for an individualized mRNA cancer treatment, providing Moderna with its strongest clinical evidence yet for an oncology business amid a decline in demand for its COVID-19 vaccines.

Intismeran autogene, which utilizes genetic information from an individual patient's tumor to create a personalized mRNA treatment, targets specific mutations that can be attacked by the immune system. In the trial, participants were randomly assigned to receive either Keytruda alone or in combination with intismeran autogene following the complete removal of stage IIB to IV melanoma via surgery.

The combination proved to have statistically and clinically significant improvements in both recurrence-free survival and distant metastasis-free survival. The companies anticipate presenting the full findings at a medical meeting later in the year, which will include data on the size and duration of the benefit, safety data, and outcomes across various patient groups.

Moderna's stock surge reflects the recognition of oncology as a key growth area for the company, which has traditionally focused on vaccine production. Despite a decline in COVID-19 vaccine sales, Merck shares also rose by about 11% on the same day, marking their strongest performance in over 17 years. Analysts at William Blair upgraded Moderna's stock to an "Outperform" rating, citing a clearer path for the company to diversify its revenue streams beyond COVID-19 products.

The melanoma trial results provide Moderna and Merck with a strong foundation for discussions with regulatory authorities, with the potential for regulatory approval and widespread clinical adoption generating significant revenue.